Your browser doesn't support javascript.
loading
Tocilizumab in HIV patient with severe COVID-19: case report.
Bertozzi, Pedro Vieira; de Oliveira Vicente, Amanda; Pereira, Amanda Siqueira; de Sant'Ana, Joao Pedro Espinha; Mano, Rafaela Braga Cabrera; Jorge, Luciana Souza; da Silva Sardenberg, Rodrigo Afonso.
Afiliação
  • Bertozzi PV; Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos-UNILAGO, Emilia Tarraf st., 340, São Jose do Rio Preto, SP, 15055-460, Brazil. pedro.vieira.1998@hotmail.com.
  • de Oliveira Vicente A; Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos, UNILAGO, São Jose do Rio Preto, SP, Brazil.
  • Pereira AS; Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos, UNILAGO, São Jose do Rio Preto, SP, Brazil.
  • de Sant'Ana JPE; Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos, UNILAGO, São Jose do Rio Preto, SP, Brazil.
  • Mano RBC; Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos, UNILAGO, São Jose do Rio Preto, SP, Brazil.
  • Jorge LS; Infectology Department, Hospital de Base, São Jose do Rio Preto, Brazil.
  • da Silva Sardenberg RA; Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos, UNILAGO, São Jose do Rio Preto, SP, Brazil.
AIDS Res Ther ; 18(1): 73, 2021 10 16.
Article em En | MEDLINE | ID: mdl-34656134
BACKGROUND: A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. CASE PRESENTATION: The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition. Intubation, hemodialysis, and tracheostomy were necessary to maintain homeostasis. In addition to regular treatment with etravirine, dolutegravir, darunavir, and ritonavir for highly active antiretroviral therapy, the patient received tocilizumab, which showed a great recovery in the patient's condition. CONCLUSION: The patient had several risk factors, such as male gender, age > 70 years, and arterial hypertension. The use of tocilizumab was of great importance in the patient's recovery since the drug increased his immune response, which is deficient, due to HIV infection.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Anticorpos Monoclonais Humanizados / Tratamento Farmacológico da COVID-19 Tipo de estudo: Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: AIDS Res Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Anticorpos Monoclonais Humanizados / Tratamento Farmacológico da COVID-19 Tipo de estudo: Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: AIDS Res Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil